[149] CODEN (CAS-USA): WJCMCF Formulation and evaluation of oral disintegrating tablets of furosemide Manish Khadka* 1 , Dharma Prasad Khanal 1 , Deepti Piya Baniya 1 , Prakash Karki 1 and Saurav Shrestha 2 1 Department of Pharmacy, Manmohan Memorial Institute of Health Sciences, Tribhuvan University, Soalteemode-44600, Kathmandu, Nepal 2 Department of Pharmacy, Institute of Medicine, Maharajgunj Medical Campus, Tribhuvan University, Maharajgunj-44600, Kathmandu, Nepal Abstract Orally disintegrating tablets of Furosemide were prepared, evaluated and the comparison of the action of different concentrations of disintegrants on disintegration and dissolution of the tablets were studied. Direct compression method was used to prepare the orally disintegrating tablets containing 20 mg of Furosemide. The formulation was conducted using different concentrations of crospovidone, croscarmellose and sodium starch glycolate as superdisintegrants and their interactions with Furosemide were also evaluated using FTIR. FTIR studies using the drug and its mixtures with the excipients showed that the peaks correlate with one another which signify that there is no interaction between the drug molecule and the excipients used. The obtained results revealed that the disintegration time of ODTs were between 9 to 59 seconds. The percentage drug content of tablets in all the formulations was found between 91.51% to 106.69%, which complies with the limits established in pharmacopoeia. The in-vitro dissolution studies show maximum release of 89.47% in formulation F3 and minimum of 77.64% in formulation F12. Higher concentration of crospovidone and croscarmellose in formulations F3 and F6 showed better dissolution properties than SSG. So by varying the concentrations of super disintegrants, oral disintegrating tablets can be formulated. Introduction Orally disintegrating tablets are the dosage forms that get disintegrated when they come in contact with the saliva present in the oral cavity. The saliva penetrates the tablets and disrupts its structural integrity which results in the release of the drug from the dosage form [1]. The rapid disintegration of the tablets in the oral cavity may be rendered by the use of super disintegrants, such as crospovidone, croscarmellose and sodium starch glycolate, thus making the dosage form favorable for the pediatric population, geriatric population, bed-ridden patients and patients with dysphagia [2]. According to the United States Food and Drug Administration, an Oral Disintegrating Tablet is defined as “A solid dosage form which contains a medicinal substance or an active ingredient which rapidly disintegrates when placed upon the tongue, usually within matter of seconds [3]. The names such as rapid dissolving, mouth dissolving and fast melt tablets has also been given to the orally disintegrating tablets. The orally disintegrating tablets disperse and disintegrate when they come in contact with the saliva present in the oral cavity that omits the use of liquid to take the tablet, to swallow the whole dosage form or to chew the tablet. This dosage form is thus beneficial to the pediatric and geriatric patients and also to those who have swallowing difficulties including dysphagia and patients with psychiatric disorders [4]. Furosemide is a loop diuretic or often called as a high ceiling diuretic used in the treatment of edematous states which prevents and treats the fluid retention in the body. The usual dosage forms of furosemide available are 20 and 40 mg tablets. Chemically Furosemide is 5-(aminosulphonyl)-4-chloro-2-[(2-fuanyl- methyl) amino] benzoic acid [5]. The Biopharmaceutics Classification System (BCS) classifies furosemide as a Class IV compound, which means that furosemide has a low solubility and a low permeability. The bioavailability of furosemide is found to be 37-70% with its peak plasma concentration (Cmax) found to be achieved within 60 to 90 min. The plasma half-life (t1/2) of furosemide is 1.3±0.8 h in healthy subjects [6]. The purpose of this study is to formulate the ODTs of Furosemide and to perform the evaluation of those formulations for different parameters. The use of the superdisintegrants i.e. Crosspovidone, Croscarmellose sodium and Sodium starch glycolate and their effects on the tablets’ disintegration and dissolution has been studied. Materials and Methods Raw materials were obtained with coordination with the Department of Pharmacy MMIHS and Lomus and Qmed Pharmaceuticals. Furosemide, MCC, sucralose and mannitol WORLD JOURNAL OF CURRENT MEDICAL AND PHARMACEUTICAL RESEARCH www.wjcmpr.com ISSN: 2582-0222 Article History: Received: 03.10.2021 Revised: 24.10.2021 Accepted: 02.12.2021 Keywords: Orally disintegrating tablet, Superdisintegrants, Furosemide, FTIR. *Corresponding Author Manish Khadka Email: maness.kdk@gmail.com DOI: https://doi.org/10.37022/wjcmpr.v3i6.202 This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License. Copyright © 2021 Author(s) retain the copyright of this article. World J Curr Med Pharm Res. 2021; 3(6): 149-156 Research Article